Finance

“Based on the current rates of success in creating new drugs for Alzheimer's disease, it could take 260 years until the next one is approved,” writes The Boston Globe’s Carolyn Johnson on the rationale for why Professor Andrew Lo is proposing a new, portfolio-based approach to Alzheimer's research.

NPR’s Jim Zarroli reports on new MIT research that explores how tax evasion techniques like round-tripping can hurt the U.S. economy.